Former Minister of Health Brings Institutional Leadership to Expand Affiliate Network Across Key Latin American Markets

Las Vegas, Nevada, [July 29, 2025] (ACCESS NEWSWIRE) — Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced the appointment of Dr. José Luis Décima as its new representative for Argentina’s northern region and Paraguay through its Global Stem Cells Group subsidiary. The strategic appointment expands RMTG’s affiliate network into underserved markets with significant growth potential.

Leadership and Market Expansion:

Dr. José Luis Décima, former Minister of Health for the province of Formosa and Director of high-complexity hospitals, brings decades of institutional experience and government healthcare leadership to RMTG’s Latin American expansion. His appointment follows RMTG’s proven affiliate model, where representatives develop regional centers, training programs, and product distribution networks.

“Argentina has played a pivotal role in our history, and now we are ready to take the next step by extending our footprint in the north and into Paraguay,” said David Christensen, CEO of RMTG. “Dr. Décima brings a wealth of experience and institutional knowledge. We expect that his leadership will be instrumental in helping us bring our therapies and educational programs to even more physicians and patients across this important region.”

Strategic Partnership Benefits:

• Institutional Credibility: Former Minister of Health brings government relations expertise and healthcare system knowledge to facilitate market entry and regulatory compliance

• Geographic Expansion: Northern Argentina and Paraguay represent underserved markets with growing demand for advanced regenerative medicine solutions

• Infrastructure Development: Plans already underway for a new regenerative medicine center in Formosa with Dr. Apóstolo and multidisciplinary team, including training programs and clinical care

• Revenue Generation: New territory adds to RMTG’s affiliate and member network spanning 30+ countries, creating multiple revenue streams through training fees, product sales, and certification programs

• ISSCA Integration: Regional representative will develop ISSCA training protocols and certification programs, leveraging RMTG’s proven education platform

Benito Novas, Founder of Global Stem Cells Group, emphasized the historical importance of Argentina in the organization’s growth: “This new alliance with Dr. Décima is the continuation of a trusted relationship — but more importantly, it’s a new beginning for bringing regenerative medicine to underserved areas with integrity and scientific rigor.”

Market Opportunity and Regional Strategy:

The appointment builds on RMTG’s successful Argentina presence, where the Company recently hosted its ISSCA Argentina 2025 event attracting hundreds of medical professionals. Dr. Décima’s government healthcare background provides strategic advantages for navigating regulatory environments and establishing institutional partnerships across the region.

“It is an honor to represent Global Stem Cells Group and ISSCA in Argentina and Paraguay,” said Dr. José Luis Décima. “The development of regenerative medicine in our region has reached a moment of maturity, and now with this alliance, we are prepared to expand that knowledge and structure into concrete action. Our focus will be on education, responsible practice, and innovation.”

The expansion aligns with RMTG’s recent momentum, including Q1 2025 sales of $1.35M representing 67% growth with operational profits of $134,000. The Company expects that its new affiliate program, commencing in Q3, will generate upfront membership fees of up to $500,000, with new members receiving turnkey assistance in setting up regenerative medicine clinics along with continuous training and support.

About RMTG:

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s integrated approach combines clinical operations, product distribution, and medical education to capitalize on the rapidly expanding global regenerative medicine market. To learn more, visit www.stemcellsgroup.com.

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to future revenues, representative appointments, market expansion in Argentina and Paraguay, or development of new regenerative medicine centers. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that Dr. Décima’s appointment will achieve projected benefits, that planned facilities will be successfully developed, or that market opportunities will materialize as anticipated. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contact: David Christensen, CEO and President Regenerative Medical Technologies Group, Inc. investor.relations@regenmedtechgroup.com | (800) 956-3935

Strategic Alliance Adds High-Value Territory to Global Network of 26 Clinics

Las Vegas, Nevada, July 21, 2025 (GLOBE NEWSWIRE) – Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medical solutions, announces its official expansion into Puerto Rico through a newly formed alliance with Dr. Juan C. Ramos and Dr. Aleida G. Nieves at the new “Global Stem Cells Group Puerto Rico.” The partnership was unveiled during a joint press conference led by GSCG’s Founder Benito Novas, RMTG’s CEO Dave Christensen, and the newly appointed representatives for Puerto Rico, Dr. Juan C. Ramos and Dr. Aleida G. Nieves, owners of Global Stem Cells Group Puerto Rico.

Financial Impact:

The Puerto Rico affiliate follows RMTG/GSCG’s proven turnkey model, where new members pay upfront fees in the 6-figure dollar range plus ongoing special supply agreements. Led by Dr. Juan C. Ramos and Dr. Aleida G. Nieves, the partnership establishes Global Stem Cells Group Puerto Rico as a key strategic entry point into Caribbean and Latin American medical markets.

Strategic Partnership Benefits:

• Immediate Revenue Impact: New affiliates generate upfront fees, ongoing fees, plus ongoing exclusive purchases of RMTG’s Cellgenic product line, creating both immediate and recurring revenue streams

• High-Value Market Entry: Puerto Rico’s $4.2 billion healthcare market offers significant growth potential, with U.S. territory status providing regulatory familiarity while maintaining competitive operational costs for medical tourism

• Proven Scalable Model: Partnership replicates RMTG’s successful network framework used across 26 clinics in 21 countries, with turnkey setup reducing risk while ensuring consistent quality standards and brand recognition

• Comprehensive Support Infrastructure: New affiliate receives complete physician training through ISSCA’s world-renowned education platform, ongoing clinical support, marketing assistance, and exclusive access to cutting-edge regenerative medicine protocols

• Strategic Geographic Positioning: Puerto Rico serves as gateway to Latin American markets while maintaining access to U.S. healthcare infrastructure, positioning RMTG for further Caribbean and Central American expansion

The partnership was announced during RMTG/GSCG’s Buenos Aires press conference, where the Company hosted its ISSCA Argentina 2025 conference attracting over 200 medical professionals. Initial plans for Puerto Rico include development of a certified training center, local product distribution network, and the first ISSCA Puerto Rico event scheduled for December 2025.

“We are excited to welcome Dr. Juan C. Ramos and Dr. Aleida G. Nieves as our official representatives for Global Stem Cells Group Puerto Rico,” said David Christensen, CEO and President. “We chose this location because of the extraordinary leadership and commitment we’ve seen in Dr. Juan C. Ramos, Dr. Aleida G. Nieves and their team at Global Stem Cells Group Puerto Rico. This alliance reflects our ongoing mission to bring regenerative medicine to every region where there is both need and readiness to embrace innovation.”

The Puerto Rico expansion builds on RMTG’s recent momentum, including Q1 2025 sales of $1.35M representing 67% growth over last year’s first quarter with operational profits of $134,000. The Company’s affiliate program generates upfront membership fees in the six figure dollar range where new members receive turnkey assistance in setting up regenerative medicine clinics in their area along with continuous training and support. Affiliate members are bound to purchase all supplies exclusively from RMTG, creating sustained recurring revenue streams.

Dr. Juan C. Ramos and Dr. Aleida G. Nieves, who now lead the GSCG Puerto Rico operations, emphasized the impact this collaboration will have on the local medical landscape: “To have the official representation of Global Stem Cells Group in Puerto Rico is a major milestone for us — not just as a clinic, but as contributors to the future of medicine on the island,” said Dr. Ramos. “We now have the opportunity to bring structured, science-based regenerative solutions to the physicians in Puerto Rico, backed by global expertise and a clear ethical framework.”

Benito Novas, Founder of Global Stem Cells Group (GSCG), reflected on the significance of this new chapter: “This is more than just a representation agreement — this is a shared commitment to raising the standard of care in Puerto Rico. From day one, our organization has believed in forming alliances with visionary leaders who are ready to embrace the future of medicine. With Dr. Ramos and Dr. Nieves at Global Stem Cells Group Puerto Rico, we’ve found exactly that.”

About RMTG:

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s affiliate program generates upfront membership fees in the six figure dollar range where new members receive turnkey assistance in setting up regenerative medicine clinics along with continuous training and support.

About ISSCA:


The International Society for Stem Cell Application (ISSCA) serves as the dedicated educational and scientific arm of Global Stem Cells Group. ISSCA is a multidisciplinary, physician-led community composed of medical professionals, researchers, and scientists who are committed to advancing the clinical application of regenerative medicine and cellular therapies. The Society plays a pivotal role in bridging the gap between scientific research and clinical practice by providing a comprehensive platform for education, certification, and international collaboration. Through hands-on training programs, academic conferences, and ongoing professional development, ISSCA promotes the responsible, ethical, and evidence-based use of stem cell protocols across the globe. Its mission is to elevate standards of care and empower healthcare providers to deliver innovative regenerative solutions to their patients.

More information: https://www.issca.us/#

About Global Stem Cells Group:


Global Stem Cells Group (GSCG) is an international consortium of regenerative medicine entities encompassing clinics, laboratories, academic institutions, and product distributors. Headquartered in the United States, GSCG operates in more than 30 countries, offering a full-spectrum approach to the advancement of cellular medicine. The organization is dedicated to democratizing access to cutting-edge regenerative therapies by integrating scientific research, physician training, and high-quality product development. GSCG’s initiatives are focused on improving patient outcomes while transforming the future of healthcare through innovation, strategic global partnerships, and a strong commitment to education. Its multifaceted infrastructure allows GSCG to support every stage of regenerative practice—from laboratory innovation to bedside application.

More information: www.stemcellsgroup.com or call +1 305 560 5331

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to its future revenues, affiliate partnerships, market expansion, or revenue generation from Puerto Rico operations. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that the Puerto Rico affiliate will achieve projected revenue targets, that market opportunities will materialize as anticipated, or that the affiliate model will continue to be successful. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price

For further information, please contact: investor.relations@regenmedtechgroup.com | (800) 956-3935

Argentina Success Validates Global Education Platform with Major Cancun Event and Six More In-Country Programs Scheduled

Las Vegas, Nevada, July 24, 2025 (ACCESS NEWSWIRE) – Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced the successful completion of its ISSCA Argentina 2025 event in Buenos Aires, which attracted hundreds of doctors and medical professionals to the Four Seasons hotel downtown. The Company also announced seven additional ISSCA training events scheduled for 2025, demonstrating continued momentum in its global physician education platform.

Event Success and Revenue Impact:

The Buenos Aires event represents RMTG’s continued expansion of its ISSCA (International Society for Stem Cell Application) education platform, which generates significant revenue through physician training, certification programs, and product sales. The event featured comprehensive training from theoretical lectures to live clinical practice, with doctors completing certification by working through real-life clinical cases guided by industry experts.

Strategic Training Platform Expansion:

• Proven Demand: Hundreds of physicians filled the Four Seasons hotel, validating market appetite for advanced regenerative medicine training

• Revenue Generation: ISSCA events drive multiple revenue streams including training fees, certification programs, and Cellgenic product sales

• Global Reach: Seven additional events scheduled across key markets including major annual event in Cancun

• Certification Value: Hands-on training with real clinical cases provides premium value proposition for medical professionals

• Product Integration: Cellgenic product line serves as official sponsor, creating direct sales opportunities during training events

“We are grateful for the attendance of some of the best doctors who seek out the latest innovations and come to learn new breakthroughs in regenerative medicine,” said David Christensen, CEO and President. “We filled the 4-Seasons hotel downtown with hundreds of doctors and medical professionals who attended this incredible event.”

Upcoming 2025 ISSCA Event Schedule:

The Company announced Seven additional ISSCA training events for 2025, expanding its global education footprint:

1. Global Event Cancun – September 11^th
2. Brazil – October 2^nd
3. Colombia – October 24^th
4. Cancun 2.0 – November  7^th
5. Saudi Arabia – November  14^th
6. Peru – November 28^th
7. Puerto Rico – December 5^th

“ISSCA is one of the world’s largest and most effective Physician Training in the Regenerative Medical Industry,” said Benito Novas, Founder of Global Stem Cells Group (GSCG). “We are honored and grateful to our whole team for the countless hours and enduring passion to consistently put on the best events in the Regenerative Medical industry.”

The Buenos Aires success builds on RMTG’s recent Q1 2025 performance that delivered $1.35M in sales representing 67% growth with operational profits of $134,000. The Company’s global education platform continues to drive both direct revenue and affiliate partnerships worldwide.

About Regenerative Medical Technologies Group, Inc. (RMTG):

RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company’s integrated approach combines clinical operations and procedures, product and equipment distribution, and medical education to capitalize on the rapidly expanding global regenerative medicine market. To learn more, visit www.stemcellsgroup.com

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the “Company”). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to its future revenues, affiliate partnerships, market expansion, or revenue generation from Puerto Rico operations. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that the Puerto Rico affiliate will achieve projected revenue targets, that market opportunities will materialize as anticipated, or that the affiliate model will continue to be successful. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company’s future revenues, results of operations, or stock price

For further information, please contact: investor.relations@regenmedtechgroup.com | (800) 956-3935

Miami, Florida– Global Stem Cells Group (GSCG), an established international organization focused on advancing regenerative medicine, is pleased to announce a new strategic collaboration with the Njinsky Medical Centre for the exclusive launch of its CELLGENIC product line in Pakistan. This collaboration represents a significant milestone in what both parties hope will be the broader introduction of regenerative technologies across South Asia and the Middle East.

Through this alliance, the Njinsky Medical Centre will serve as the exclusive distributor of CELLGENIC-branded exosome products in Pakistan, a country recognized as one of the most populous and dynamic healthcare markets in the region. Both organizations are committed to a shared vision: to explore opportunities for innovation, improve accessibility to emerging therapies, and support the responsible and ethical application of regenerative medicine technologies.

---

A Collaborative Framework for Long-Term Development

The five-year distribution agreement outlines a coordinated rollout strategy that includes the introduction of CELLGENIC’s full regenerative medicine product portfolio. The agreement also provides for the development of multiple stem cell and regenerative treatment centers across the country, the organization of four physician training sessions annually, and the establishment of an international medical congress in Pakistan focused on education and awareness in the field of cellular therapies.

“We believe this collaboration may offer a sustainable and scalable model for bringing scientifically grounded regenerative solutions to new markets,” said Benito Novas, CEO of Global Stem Cells Group and founder of CELLGENIC. “Through strategic alignment with local institutions like the Njinsky Medical Centre, we hope to support healthcare professionals by expanding access to training and emerging technologies.”

---

The CELLGENIC Portfolio: A Platform for Innovation

As part of the agreement, the Njinsky Medical Centre will receive access to the complete CELLGENIC product range, including lyophilized and liquid-form exosome therapies. These formulations, developed by GSCG through international research and quality-controlled processes, are based on exosomes derived from human umbilical cord stem cells and are produced in accordance with established industry standards.

While results may vary depending on the clinical application, exosomes are being explored for their potential role in supporting tissue regeneration, managing inflammatory conditions, and contributing to overall cellular communication. CELLGENIC’s products are currently offered for investigational and physician-directed use in countries with relevant regulatory frameworks that allow their application.

Key product features include:

• Sourced from human umbilical cord-derived MSCs
  
  
• Available in both liquid and lyophilized (freeze-dried) formulations
  
  
• Manufactured under rigorous quality assurance protocols
  
  
• Intended for use in professional medical settings under clinical guidance
  
  

---

Njinsky Medical Centre’s Commitment to Local Advancement

As part of the implementation plan, the Njinsky Medical Centre will oversee efforts to meet Pakistan’s regulatory and patient safety standards, while aiming to localize certain stages of production. These efforts are intended to align with national healthcare priorities and ensure the ethical and secure handling of all biological materials.

“We are honored to collaborate with Global Stem Cells Group and to take part in introducing these technologies to our region,” said Syed Asad Ali, Chief Executive at Njinsky Medical Centre. “This agreement provides us with access to training programs, certifications, and a product platform that we hope will support Pakistani healthcare professionals in offering advanced, research-driven options to their patients.”

Njinsky’s long-term goal includes the expansion of CELLGENIC’s presence across Pakistan, and the integration of GSCG’s broader business lines—ranging from biologics to medical equipment and physician training.

Usman Shah, Managing Partner of Njinsky Medical Centre, added: “We expect this collaboration to serve as a gateway for growth, research, and the integration of regenerative care into clinical practice, in ways that are both cost-conscious and medically responsible.”

---

Structured Rollout and Training Initiatives

The official launch of the CELLGENIC product line in Pakistan is anticipated for August 2025, with preliminary activities already underway. These include a series of pilot programs and ISSCA-certified training sessions for selected healthcare professionals. The International Society for Stem Cell Application (ISSCA), the educational division of GSCG, will oversee physician training as part of its continuing education initiatives.

Key upcoming milestones include:

• ISSCA Training Programs – Hands-on certification sessions for Pakistani physicians
  
  
• Pilot Program Implementation – Initial clinical protocols rolled out in selected centers
  
  
• Official Launch Event – High-level medical gathering scheduled for August 2025
  
  
• Regional Outreach – Exploration of expansion opportunities in neighboring markets
  
  

Through these initiatives, both organizations seek to lay the foundation for a robust and sustainable regenerative medicine ecosystem in Pakistan, one that may serve as a reference model for future regional partnerships.

---

About Global Stem Cells Group and CELLGENIC

Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a multi-division biotechnology company with a presence in more than 40 countries. As an international consortium, the company is dedicated to stem cell research, physician education, clinical research, and the commercialization of advanced regenerative products.

The organization brings together several specialized companies under one umbrella to offer innovative patient treatment protocols, hands-on training programs, and regulatory consulting. Its flagship brand, CELLGENIC, includes a broad range of biologic solutions—from exosomes to stem cell kits, collagenase systems, and platelet-rich plasma (PRP) kits—developed to support physicians in the evolving field of regenerative healthcare.

GSCG is committed to expanding access to regenerative medicine worldwide and supports physicians through certification programs, conferences, and scientific collaboration.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/

More information: www.stemcellsgroup.com | www.issca.us

---

About the Njinsky Medical Centre

The Njinsky Medical Centre (also known as the Njinsky Stem Cell Centre) is a Pakistan-based institution dedicated to investigating and applying stem cell and exosome therapies for complex and chronic conditions. With ISO 9001 (Quality Management Systems), ISO 14644 (Cleanroom Standards), ISO 15189 (Medical Laboratory Standards), International Accreditation Forum (IAF), and Institute of Global Certification (IGC), offering globally recognized excellence in regenerative medicine. Njinsky has a GMP compliant ISO-certified, biosafety level-2 laboratories and a team of licensed medical professionals, the Medical Centre operates at the intersection of clinical practice and global research. Njinsky’s mission is to responsibly introduce the most promising international therapies to the local context, supporting recovery and quality of life for patients where conventional treatments may offer limited results.

More information: www.stemcellsgroup.com or call +1 305 560 5331

---

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL – 2025 – The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), is pleased to announce the second edition of its hands-on certification in Regenerative, Functional, and Aesthetic Gynecology, which is expected to bring together physicians from across the globe in Cancún, Mexico, from May 23 to 25, 2025.

This advanced training program is curated by Dr. Jorge Alberto Elías, a respected figure in the field of urogynecology and regenerative medicine, and is designed to offer medical professionals a comprehensive and clinically relevant learning experience that aligns with the evolving demands of women’s health.

---

Comprehensive Three-Day Structure Focused on Practical Application

The training will span three intensive days, offering participants a carefully planned balance between academic content and real-world application:

• Day 1: Theoretical Sessions
   Participants will attend in-depth lectures and engage in discussions exploring the latest developments in regenerative gynecology. Topics will include clinical protocols, biological mechanisms, patient selection, and the integration of regenerative therapies into gynecological and aesthetic practice.
  
  
• Days 2 & 3: Practical Hands-On Training
   Attendees will take part in live demonstrations and perform procedures under the guidance of expert faculty. These sessions will focus on applying protocols in real clinical scenarios, allowing participants to gain confidence in techniques that combine functionality and aesthetics in women’s care.
  
  

This format is intended to promote deep learning, peer exchange, and direct observation of the regenerative strategies being taught.

---

Global Reach Through Hybrid Format

ISSCA recognizes the importance of accessibility and global inclusion in medical education. To this end, the training will be offered in a hybrid format, allowing physicians from different regions to participate in the theoretical component remotely through a secure online platform. Those who attend in person will benefit from the full immersive experience, including access to live patient procedures, faculty interaction, and case-based mentorship.

---

Expertise You Can Build On

Dr. Jorge Alberto Elías brings more than 30 years of clinical and academic experience to this program. He holds certifications from SOGIBA and the National Academy of Medicine and has been honored by numerous international medical societies. His practice in Buenos Aires, Argentina, Laser Hormonas y Bienestar, specializes in regenerative therapies, hormonal modulation, and aesthetic gynecology.

His leadership in this training is expected to deliver a well-rounded curriculum based on real-world practice, cutting-edge techniques, and evidence-based strategies.

---

Key Topics Expected to Be Covered:

• Umbilical cord donor-derived stem cells in gynecological therapies
  
  
• Exosomes and regenerative medicine applications in women’s health
  
  
• Advanced treatment protocols for lichen sclerosus
  
  
• Aesthetic gynecology procedures and rejuvenation techniques
  
  
• Personalized hormonal modulation and endocrine balance strategies
  
  
• Intimate rejuvenation using laser and radiofrequency technologies
  
  
• Minimally invasive approaches to urinary incontinence
  
  
• Genital cosmetic surgery and aesthetic enhancements
  
  
• Sexual wellness recovery through regenerative medicine protocols
  
  

These topics are intended to provide physicians with practical tools to expand their services and address a broader range of functional, aesthetic, and emotional aspects related to women’s health.

---

A Vision for the Future of Women’s Care

“We hope this training will serve as a platform for physicians to explore new approaches in gynecologic care, supported by regenerative science,” said Benito Novas, Founder of ISSCA and CEO of Global Stem Cells Group. “By learning from Dr. Elías, we expect participants will gain clinical knowledge that can enhance their perspective and elevate the level of care they provide.”

Dr. Elías added, “This program is the result of decades of continuous work and research in the area of women’s wellness. We believe that combining functional and aesthetic aspects of gynecology through regenerative strategies may open new doors for physicians and improve patient satisfaction in meaningful ways.”

About the International Society for Stem Cell Application (ISSCA)

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary global network of physicians and scientists committed to the advancement of regenerative medicine and stem cell-based therapies. ISSCA’s mission is to lead in certification, education, research, and training, promoting high standards and best practices in the field. With members in over 35 countries, the organization fosters collaboration and knowledge-sharing to support the safe and effective implementation of cutting-edge cellular treatments in clinical practice.

About Global Stem Cells Group (GSCG)

Global Stem Cells Group (GSCG) is an international consortium dedicated to stem cell research, clinical applications, and physician education. The organization brings together several specialized companies under one umbrella to offer innovative patient treatment protocols, hands-on training programs, and regulatory consulting. GSCG is committed to expanding access to regenerative medicine worldwide and supports physicians through certification programs, conferences, and scientific collaboration.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/

To learn more about Global Stem Cells Group, Inc.’s companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.

---

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

---

Register Now
 Seats are limited for this high-demand certification. To reserve your spot or to learn more, please visit: www.issca.com

Miami, Florida — Global Stem Cells Group (GSCG), together with the International Society for Stem Cell Application (ISSCA), is pleased to share the success of the recent International Regenerative Medicine Conference, held on March 7 and 8 at the luxurious Secrets The Vine Cancún, located in the heart of the Hotel Zone in Cancún, Mexico.

This two-day event brought together a distinguished lineup of internationally recognized experts in regenerative medicine and biotechnology, offering physicians a unique combination of theoretical lectures and hands-on training sessions. The conference welcomed participants from over 14 countries including the United States, Dominican Republic, Colombia, El Salvador, Puerto Rico, Argentina, Ecuador, Costa Rica, Peru, Bolivia, Honduras, and Panama.

The March 7 segment focused on the theoretical foundations of regenerative medicine, featuring lectures by global leaders in the field. Among the featured speakers:

• Rafael González, Ph.D. (USA), presented a scientific review on Natural Killer Cells.
  
  
• Dr. Matt Halpert, Ph.D. (USA) shared insights on Dendritic Cells in the treatment of cancerous tumors.
  
  
• Mercedes Kweh, Ph.D. and Frederick Kweh, Ph.D. (USA) addressed key considerations in Exosomes and Secretome Therapeutics.
  
  
• Dr. Iván Ibáñez (Spain) explored the frontiers of Biohacking, Metabolism, and Lipedema.
  
  
• Dr. Andrea Lapeire (Argentina), Dr. Julio Ferreira (Argentina), Dr. Mario Ojeda (Chile), and Dr. Martín Estévez (Argentina) offered valuable clinical perspectives across various regenerative medicine applications.
  
  

These were just some of the many international experts who shared their insights during the day. The program featured a diverse group of speakers from different parts of the world, contributing to a truly global exchange of knowledge and innovation.

The day concluded with an interactive Q&A session and a special Social MedConnect experience at Coco Bongo, a well-known nightclub and entertainment venue in the area, providing attendees and speakers with an engaging evening of networking and entertainment.

On March 8, the focus shifted to hands-on training, with three fully booked parallel tracks conducted across Cellular Hope Institute, Immunocine, and ReHealth facilities in Cancún.

These included:

• Advanced Aesthetic Regenerative Medicine, led by Dr. Andrea Lapeyre and Dr. Julio Ferreira, covered the use of exosomes, allogeneic fibroblasts, autologous and allogeneic stem cells, peptides, and advanced aesthetic protocols.
  
  
• Advanced Cellular Therapy, with sessions hosted at Cellular Hope Institute, ImmunoSynth, and ReHealth, featured in-depth modules on Dendritic Cells, Natural Killer Cells, and Exosomes, led by experts including Dr. Matt Halpert, Dr. Rafael González, Dr. Frederick Kweh, and Dr. Mercedes Kweh.
  
  
• A third track, led by Dr. Iván Ibáñez, offered a specialized look into Biohacking, Peptides, Obesity, and Metabolism.

Benito Novas, Founder of ISSCA and CEO of Global Stem Cells Group, emphasized ISSCA’s mission, stating:

 “We believe that by creating platforms for international collaboration and education, we are helping physicians around the world access the latest advancements in regenerative medicine. Our mission is to foster a global standard of care through training, innovation, and scientific exchange.”

With the conference fully booked and hands-on courses filled to capacity, GSCG and ISSCA extend their sincere thanks to all attendees, speakers, and collaborators who made this event a remarkable experience.

We expect that future editions will continue to build on this momentum, further expanding access to the latest tools and protocols in regenerative medicine across the globe.

For more information about upcoming conferences and certification programs, please visit www.issca.com.

---

About Benito Novas

Benito Novas is a global entrepreneur and a leading figure in regenerative medicine, Founder of  International Society for Stem Cell Application(ISSCA) and CEO of Global Stem Cells Group. He has been instrumental in expanding the reach of regenerative therapies worldwide, helping thousands of physicians integrate stem cell treatments into their practices through training programs and strategic support. Under Novas’s leadership, access to regenerative medicine education and technology has grown exponentially across the globe, solidifying his reputation as a key innovator in the field.

About the International Society for Stem Cell Application (ISSCA)

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary global network of physicians and scientists committed to the advancement of regenerative medicine and stem cell-based therapies. ISSCA’s mission is to lead in certification, education, research, and training, promoting high standards and best practices in the field. With members in over 35 countries, the organization fosters collaboration and knowledge-sharing to support the safe and effective implementation of cutting-edge cellular treatments in clinical practice.

About Global Stem Cells Group (GSCG)

Global Stem Cells Group (GSCG) is an international consortium dedicated to stem cell research, clinical applications, and physician education. The organization brings together several specialized companies under one umbrella to offer innovative patient treatment protocols, hands-on training programs, and regulatory consulting. GSCG is committed to expanding access to regenerative medicine worldwide and supports physicians through certification programs, conferences, and scientific collaboration.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG. https://finance.yahoo.com/quote/RMTG/

To learn more about Global Stem Cells Group, Inc.’s companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.

About ReHealth

ReHealth is a premier regenerative medicine center based in Cancún, Mexico, recognized for its expertise in stem cell therapy, natural killer (NK) cell treatments, and exosome-based protocols. The clinic offers personalized therapeutic solutions backed by years of research and clinical development. With a state-of-the-art laboratory and treatment facility that adheres to international quality standards, ReHealth provides advanced regenerative care in a safe, patient-centered environment, attracting patients from around the world.

About Immunocine

Immunocine Cancer Center is a cutting-edge medical institution in Cancún specializing in advanced cancer immunotherapy. Led by Dr. Matthew Halpert, the center has developed a novel dendritic cell therapy that reprograms the patient’s immune cells to recognize and attack cancer without the use of foreign drugs or genetic modification. This proprietary approach is currently undergoing clinical evaluation and has shown promising results in treating challenging cancers. ImmunoCine continues to push the boundaries of immune-based regenerative treatments.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL – November 2024 – Global Stem Cells Group (GSCG), a recognized leader in
regenerative medicine and cellular therapies, is pleased to announce the upcoming launch of a
new clinic, set to open on November 23, 2024, in Dubai. This strategic initiative represents a
significant expansion of GSCG’s global footprint, as it seeks to offer advanced regenerative
solutions to new and vital markets.

The new clinic, located at the Hyatt Hotel in Jumeirah, is poised to become a hub for cutting-
edge regenerative treatments. The clinic aims to provide a comprehensive range of therapies,
including stem cell treatments, exosome applications, natural killer (NK) cell therapies, aesthetic
procedures, and interventions focused on promoting longevity. GSCG aspires to enhance
patient access to these innovative treatments across the region.

ISSCA to Host Conference in Dubai on November 22 and 23 Using Global Stem Cells Group’s Facilities

The International Society for Stem Cell Application (ISSCA), the educational division of Global
Stem Cells Group, will host a two-day conference as part of its 2.0 series, featuring the latest
advancements in regenerative medicine. Scheduled for November 22 and 23, this event will
include theoretical sessions on the first day at the Le Méridien Dubai Hotel & Conference
Centre, followed by practical hands-on demonstrations at the new Global Stem Cells Group
clinic on the second day. The hands-on portion, taking place on November 23, will provide
attendees with the opportunity to apply their knowledge directly in a clinical setting, under the
guidance of top experts in regenerative medicine.

The conference will feature top speakers in the field, who will share their insights and
advancements in various areas of regenerative medicine. Topics covered at the conference
include NK Cells, allogeneic PRP, human placenta, nanorevive, progenicell, peptides, CAR-T
cells, 3D bioprinting, biohacking, Wharton’s jelly, young donor plasma, and exosomes MSC.
This comprehensive agenda is designed to provide in-depth knowledge on cutting-edge
therapies such as peptides, NK cells, donor-derived stem cells, exosomes, and other advanced
treatment modalities. ISSCA’s 2.0 series seeks to equip medical professionals with updated
knowledge and skills in the most recent developments in regenerative therapies.

“We hope that this new clinic in Dubai will establish itself as a center of excellence, not only for
treatment but also for continuous education,” said Benito Novas, founder and CEO of Global
Stem Cells Group. “We believe this initiative will empower both doctors and patients by
providing access to innovative regenerative solutions. We expect it to be a meaningful milestone
in expanding our mission to deliver transformative medical therapies globally.”

A Distribution Hub for Cellgenic Products in the Middle East

The Dubai clinic is expected to serve as a key distribution center for Cellgenic products,
including the registered lyophilized exosome product. The goal is to enable efficient local and
international distribution, facilitating access to advanced regenerative products throughout the
region.

The Growing Global Demand for Regenerative Medicine

The regenerative medicine sector continues to grow, driven by increasing demand for
treatments that support healing, promote longevity, and improve overall health. With over 15
years of experience, Global Stem Cells Group aims to contribute meaningfully to this evolving
field by offering comprehensive solutions designed to address complex conditions and enhance
patient quality of life.

The Dubai clinic is expected to offer an extensive range of therapies, including:
● Mesenchymal Stem Cell (MSC) therapies, believed to promote tissue repair and overall
health.
● Exosome therapies, anticipated to support aesthetic enhancements and orthopedic
recovery.
● Natural Killer (NK) cell therapies, which aim to enhance immune system function.
● Anti-aging and longevity treatments, combining cellular therapies with therapeutic
peptides.
● Platelet-Rich Plasma (PRP) injections, expected to accelerate healing and rejuvenation.
● Specialized therapeutic peptides, aimed at addressing specific health conditions.

Dubai as a Promising Destination for Medical Tourism

Dubai’s international reputation as a premier destination positions it well to attract patients
seeking advanced regenerative treatments. GSCG anticipates that the new clinic will draw
interest from medical tourists worldwide, offering tailored treatment plans for conditions such as
autoimmune disorders, orthopedic injuries, and skin rejuvenation. The combination of innovative
medical solutions and a patient-centric approach is expected to make the Dubai clinic a vital
part of the city’s emerging status as a hub for advanced healthcare.
About Global Stem Cells Group
Founded by Benito Novas, Global Stem Cells Group seeks to advance the field of regenerative
medicine globally. With a robust presence across continents, the organization provides both
treatments and educational programs aimed at empowering doctors, researchers, and patients.
Through ISSCA, GSCG conducts specialized training, certification, and hands-on workshops
designed to promote best practices in the application of cellular therapies.
For more information about the Dubai clinic opening, ISSCA training event, or Global Stem Cells
Group, please visit the Global Stem Cells Group website.

Global Stem Cells Group is a publicly traded company operating under the symbol RMTG.
https://finance.yahoo.com/quote/RMTG/

To learn more about Global Stem Cells Group, Inc.’s companies, visit our website
www.stemcellsgroup.com or call +1 305 560 5331.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”.
Forward-looking statements include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions, or any other information relating to our
future activities or other future events or conditions. These statements are based on current
expectations, estimates, and projections about our business based partly on assumptions made
by management. These statements are not guarantees of future performance and involve risks,
uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and
results may and are likely to differ materially from what is expressed or forecasted in forward-
looking statements due to numerous factors. Any forward-looking statements speak only as of
the date of this news release, and The Global Stem Cells Group undertakes no obligation to
update any forward-looking statement to reflect events or circumstances after the date of this
news release. This press release does not constitute a public offer of any securities for sale.
Any securities offered privately will not be or have not been registered under the Act and may
not be offered or sold in the United States absent registration or an applicable exemption from
registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA), a division of the Global Stem Cells Group (GSCG), is excited to announce its upcoming international conference on Regenerative Medicine and Cellular Therapies, set to take place in Buenos Aires, Argentina, on October 25 and 26, 2024. This event promises to be a pivotal gathering for medical professionals from around the world, offering a full day of expert-led presentations followed by an immersive day of hands-on training.

A Hub of Innovation and Knowledge in Regenerative Medicine

Regenerative medicine is rapidly transforming the healthcare landscape, offering revolutionary treatments that can repair or replace damaged tissues and cells, opening new avenues for both doctors and patients. This conference provides an exceptional platform for global experts to share the latest advancements, breakthrough research, and clinical applications in regenerative medicine and cellular therapies. For medical professionals, attending this event will enable them to expand their knowledge in regenerative medicine to enhance their practice, and improve patient outcomes.

Expanding the Reach of Regenerative Medicine

Events like ISSCA’s Buenos Aires conference play a crucial role in the global expansion of regenerative medicine. For doctors, this is an opportunity to learn about cutting-edge treatments, innovative technologies, and the most recent regulatory frameworks. With practical insights into therapies like stem cell treatments, exosomes, and peptide-based interventions, physicians can bring these advancements directly into their practices, benefiting their patients with pioneering care.

For patients, the expansion of regenerative medicine means improved access to therapies that can treat a wide range of conditions— from chronic diseases to acute injuries, and even aesthetic applications. By bridging the gap between research and clinical practice, events like this accelerate the adoption of novel treatments that enhance both the quality of care and the possibilities for recovery.

“We have been conducting conferences in this incredible country for 15 years,” said Benito Novas, Vice President of ISSCA. “Buenos Aires has always welcomed us with open arms and great warmth. I love this city, and Argentina remains one of our most important partners in advancing the science of regenerative medicine.”

Key Topics to Be Covered at the Conference:

• Peptides: The Next Frontier in Regenerative Therapies
  Explore the burgeoning field of peptide-based therapies and their application in various medical specialties, offering new options for patient treatment and recovery.
• Exosomes: The Future of Cellular Medicine
  Discover how exosomes, tiny extracellular vesicles, are revolutionizing medicine, especially in facial rejuvenation, wound healing, and orthopedic therapies.
• Tissue Engineering: A New Era of Medical Innovation
  Attendees will learn how tissue engineering is shaping the future of regenerative medicine, creating new possibilities for tissue regeneration and clinical applications.
• Autologous Mesenchymal Stem Cell Applications
  A deep dive into the use of autologous mesenchymal stem cells in treating neurological disorders, spinal injuries, and chronic illnesses, with real-world examples of successful outcomes.
• Regenerative Therapies in Sports Medicine
  Learn about cutting-edge regenerative treatments in sports medicine, including stem cell and exosome therapies that accelerate recovery and enhance performance.
• Venous Ulcer Treatment through Regenerative Medicine
  Attendees will explore advanced treatments for chronic wounds, focusing on venous ulcers and how regenerative therapies offer improved healing rates.
• Advances in Genital Reconstructive Surgery
  This session will focus on the innovative use of regenerative therapies in genital reconstructive surgery, improving patient outcomes in gynecological health.
• Hands-On Training: Practical Applications of Regenerative Medicine
  Engage in live demonstrations and hands-on training in key areas such as adipose tissue processing, bone marrow extraction, exosome-based therapies, and fibroblast implants.

The Role of Events in Driving Global Change

ISSCA’s annual conferences are more than just gatherings of experts; we believe they are pivotal moments that drive the global expansion of regenerative medicine. By fostering a community of innovation, collaboration, and knowledge-sharing, ISSCA hopes to support the widespread adoption of new technologies and treatments, ultimately benefiting patients.

“Events like our Buenos Aires conference help build a network of professionals committed to advancing patient care through regenerative medicine,” added Novas. “Our aim is to provide medical practitioners with the knowledge and tools necessary to adopt innovative therapies.”

Join Us in Buenos Aires

ISSCA’s International Conference on Regenerative Medicine and Cellular Therapies is expected to be an invaluable experience for healthcare professionals looking to stay informed on the latest developments in medical science. The conference will conclude with a gala dinner and certificate presentation for attendees.

For more information and to register, visit: www.issca.com

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, FL – September 2024 –The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), is pleased to announce the launch of its new training series, Mastering Next-Generation Cellular Therapies and Regenerative Medicine 2.0. This training will be held in two prominent locations: Cancun, Mexico, on October 4th and 5th, 2024, followed by Dubai, UAE, on November 22nd and 23rd, 2024.

Building on ISSCA’s long-standing commitment to advancing regenerative medicine, this training series aims to provide participants with the most up-to-date knowledge and techniques in the field. This 2.0 iteration of ISSCA’s training is designed to focus on the next generation of cellular therapies, with the goal of equipping healthcare professionals with the tools necessary to explore and incorporate these innovations into their practices. The agenda for this training is structured to present the most recent advancements, offering attendees both theoretical knowledge and practical experience in cutting-edge therapies.

Key Topics to be Covered:

• NK Cells for Anti-Aging and Immune Support: This session is expected to provide insights into the emerging applications of NK cells in enhancing immune responses and supporting anti-aging treatments.
• Progenicell and Nanorevive Technologies: These innovative technologies will be introduced, highlighting their potential roles in tissue repair and cellular recovery.
• Peptides for Longevity and Tissue Healing: Participants will explore the latest applications of peptides, which may contribute to improved tissue regeneration, reduced inflammation, and overall health optimization.
• Wharton’s Jelly in Regenerative Medicine: Attendees will learn about the promising uses of Wharton’s Jelly in regenerative medicine, particularly in addressing degenerative conditions.
• Biohacking for Medical Optimization: This session will delve into biohacking principles and their potential integration into modern clinical practices for enhanced patient outcomes.

The Importance of Staying at the Forefront of Cellular Therapies

In light of the rapidly evolving landscape of regenerative medicine, it is increasingly important for medical professionals to remain at the forefront of technological advancements. This training seeks to support clinicians in staying updated with the latest developments in the field, which may have a significant impact on improving patient outcomes. By mastering next-generation therapies such as NK cells, peptides, and Wharton’s Jelly applications, we believe attendees will be better positioned to explore innovative treatment options in their clinical practices.

ISSCA’s Mission and Impact

ISSCA is dedicated to advancing the science and application of cellular therapies and regenerative medicine. The organization continuously strives to bring the most current developments to healthcare professionals, thereby fostering the adoption of advanced techniques that may improve patient care. Through ongoing research, ISSCA endeavors to develop new tools, methodologies, and educational resources that will empower doctors to enhance their medical practices.

The impact of ISSCA’s work extends across the global medical community, offering practitioners access to the most up-to-date therapies and enabling them to stay ahead of the curve in this rapidly changing field. By facilitating this comprehensive training, ISSCA aims to contribute to the ongoing professional development of doctors and researchers, ensuring that they are equipped with the latest knowledge and techniques in regenerative medicine.

Event Highlights:

• Comprehensive coverage of topics including NK Cells, Peptides, Progenicell, and other emerging therapies;
• Hands-on training sessions, designed to offer practical experience in next-generation regenerative treatments;
• Two international training opportunities: Cancun, Mexico, and Dubai, UAE;
• ISSCA’s latest research-driven content, developed to support practitioners in staying informed of the latest advancements in the field;
• Certification upon completion, recognizing expertise in cellular therapies and regenerative medicine; and
• Networking opportunities with global leaders and experts in the field.

Event Details:

• Cancun, Mexico: October 4 & 5, 2024
• Dubai, UAE: November 22 & 23, 2024
• Contact: For further information and registration, please visit www.issca.com or contact info@stemcellsgroup.com | +1 (754) 799 4946

ISSCA anticipates that these training events will provide a valuable opportunity for healthcare professionals, clinicians, and researchers to gain essential insights into the future of regenerative medicine. Early registration is encouraged due to limited capacity.

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Miami, Florida – The International Society for Stem Cell Application (ISSCA) is pleased to announce that an advanced training course on Functional Regenerative Medicine and Obesity will be held on October 13 and 14, 2024, at the Cellular Hope Institute in Cancun, Mexico. This two-day, immersive course aims to introduce healthcare professionals to innovative and integrative approaches to managing obesity, combining functional medicine and regenerative therapies.

Tackling a Global Health Crisis with New Approaches

With more than 650 million adults worldwide classified as obese, according to the World Health Organization (WHO), obesity has become one of the most urgent health challenges today. It not only increases the risk of chronic conditions such as cardiovascular disease and diabetes but also disrupts various bodily systems, contributing to metabolic dysfunction and inflammation. ISSCA’s upcoming training is designed to explore alternatives that go beyond conventional treatments, focusing on the root causes of obesity and offering patient-centered solutions.

Open to All Medical Specialties

The course is designed to be accessible to healthcare professionals across all specialties, as obesity can impact the function of multiple bodily systems. Whether practitioners are focused on primary care, regenerative medicine, or other fields, ISSCA believes that this training will provide valuable insights into how obesity-related issues can be addressed through functional and regenerative techniques.

Course Highlights: Topics and Training

• Non-Endoscopic Gastric Balloon Placement
  Led by Dr. Mario Ojeda, this session will introduce non-invasive gastric balloon techniques that offer an alternative for managing obesity. Participants will explore patient assessment, technique, post-procedure care, and the importance of psychological and nutritional support. Live demonstrations and case studies will provide participants with practical, real-world knowledge.
• Regenerative Therapies for Obesity and Inflammation
  Dr. Silvina Pastrana will discuss how regenerative medicine may be used to support weight management by addressing underlying inflammation, a common contributor to obesity. Attendees will learn about the potential use of exosome-based treatments and peptide therapies such as semaglutide, tirzepatide, ipamorelin, and MOTS-C, which are emerging as alternatives in the field of metabolic regulation.
• IV Therapy and Nutritional Supplementation
  Attendees will also explore IV therapies that may enhance metabolic function and support weight management efforts. Dr. Pastrana will discuss detox drips, metabolic boosters, and antioxidants, and how these therapies could complement other treatments for patients struggling with obesity.
• Functional Medicine and Gut Health
  Dr. Andrea Marquez will focus on functional medicine’s role in treating obesity, emphasizing gut health and its connection to weight management. Topics will include insulin resistance, leaky gut syndrome, and common nutritional deficiencies. Attendees will learn how addressing these root causes could potentially lead to more effective and sustainable weight management strategies for patients.

A Holistic Approach to Patient Wellness

This course is expected to emphasize the importance of treating obesity through a comprehensive approach that addresses both metabolic function and overall patient wellness. ISSCA hopes that by incorporating regenerative medicine and functional treatments, healthcare providers can offer patients alternative, integrative solutions that target the root causes of obesity rather than relying on conventional methods alone.

Hands-On Experience and Certification

Participants will have the opportunity to engage in hands-on training sessions, including live demonstrations of non-invasive gastric balloon placement, IV therapies, and peptide treatments. At the conclusion of the course, attendees will receive a digital certificate of completion, along with access to recorded class videos and additional supporting documentation for ongoing reference.

A Step Toward New Solutions in Obesity Management

As obesity continues to rise globally, ISSCA aims to provide healthcare professionals with new strategies and alternatives that could help address this growing crisis. The Functional Regenerative Medicine and Obesity course is a step toward integrating holistic, patient-centered treatments into clinical practice.

About ISSCA

The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.

ISSCA’s mission is to promote the benefits of stem cell medicine to patients globally, ensure the quality and uniformity of regenerative medicine practices, and establish itself as a global leader in the certification and education of medical professionals in this field. The organization is a distinguished division of the Global Stem Cells Group (GSCG) and has over 15 years of experience in the industry, making significant contributions to the advancement and dissemination of regenerative medicine knowledge and practices.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.